LLY

1,057.79

-1.63%↓

JNJ

205.59

-0.49%↓

ABBV

224.87

-1.27%↓

UNH

323.52

-1.98%↓

AZN

90.48

-2.43%↓

LLY

1,057.79

-1.63%↓

JNJ

205.59

-0.49%↓

ABBV

224.87

-1.27%↓

UNH

323.52

-1.98%↓

AZN

90.48

-2.43%↓

LLY

1,057.79

-1.63%↓

JNJ

205.59

-0.49%↓

ABBV

224.87

-1.27%↓

UNH

323.52

-1.98%↓

AZN

90.48

-2.43%↓

LLY

1,057.79

-1.63%↓

JNJ

205.59

-0.49%↓

ABBV

224.87

-1.27%↓

UNH

323.52

-1.98%↓

AZN

90.48

-2.43%↓

LLY

1,057.79

-1.63%↓

JNJ

205.59

-0.49%↓

ABBV

224.87

-1.27%↓

UNH

323.52

-1.98%↓

AZN

90.48

-2.43%↓

Home・Aandelen Lijst・Arrowhead Pharmaceuticals Inc

Arrowhead Pharmaceuticals Inc

Gesloten

SectorGezondheidszorg

56.12 6.59

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

52.26

Max

57.22

Belangrijke statistieken
By Trading Economics
Inkomsten	-547M -179M
Verkoop	-515M 28M
Winstmarge	-643.397
Werknemers	609
EBITDA	-546M -148M

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	-7.02% downside

Marktinformatie
By TradingEconomics
Marktkapitalisatie	3.8B 6.1B
Vorige openingsprijs	49.53
Vorige sluitingsprijs	56.12

Technische score

By Trading Central

Vertrouwen

Weak Bearish Evidence

11.5 / 12.23 Steun & Weerstand

Arrowhead Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

1 dec 2025, 21:16 UTC

Acquisities, Fusies, Overnames

Marsh McLennan Agency Acquires Three Hawaii-Based Insurance Brokerages

1 dec 2025, 18:51 UTC

Belangrijke Marktbewegers

Shopify Stock Falls on Cyber Monday System Outages

1 dec 2025, 23:47 UTC

Marktinformatie

Nikkei May Rise on Bargain Hunting -- Market Talk

1 dec 2025, 23:27 UTC

Acquisities, Fusies, Overnames

Genting Bhd. Stake in Genting Malaysia Now at 73.13% Vs. 49.36% Ahead of Take Private Offer Made in October

1 dec 2025, 23:26 UTC

Acquisities, Fusies, Overnames

Genting Bhd.: Offer to Take Genting Malaysia Private Closed on Dec.1

1 dec 2025, 23:25 UTC

Acquisities, Fusies, Overnames

Bitcoin Rout Picks Up Steam as Investors Fret Over a New 'Crypto Winter' -- WSJ

1 dec 2025, 21:52 UTC

Acquisities, Fusies, Overnames

Wood Partners Announces Itochu Corp. Purchase of 19.5% of Wood Partners

1 dec 2025, 21:42 UTC

Acquisities, Fusies, Overnames

Goldman's Latest Acquisition Is a $2 Billion Bet on Active ETFs -- Barrons.com

1 dec 2025, 21:41 UTC

Marktinformatie

Canada's GDP Revisions Mean Lower Debt-to-GDP Ratio, Better Productivity -- Market Talk

1 dec 2025, 21:41 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

1 dec 2025, 21:41 UTC

Marktinformatie

Canada's GDP Revisions Mean Lower Debt-to-GDP Ratio, Better Productivity -- Market Talk

1 dec 2025, 21:17 UTC

Acquisities, Fusies, Overnames

Commercial Metals Expects to Close Foley Products Deal by End of 2025 >CMC

1 dec 2025, 21:17 UTC

Acquisities, Fusies, Overnames

Commercial Metals Completes Acquisition of Concrete Pipe & Precast for $675M Cash >CMC

1 dec 2025, 21:15 UTC

Acquisities, Fusies, Overnames

Commercial Metals Completes Acquisition Of Concrete Pipe & Precast, LLC >CMC

1 dec 2025, 20:15 UTC

Marktinformatie

Natural Gas Turns Positive Amid Mixed Weather Trends -- Market Talk

1 dec 2025, 20:00 UTC

Acquisities, Fusies, Overnames

Marsh McLennan Agency Acquires Three Hawai'i-based Insurance Brokerages >MMC

1 dec 2025, 18:54 UTC

Marktinformatie

Silver Hits New Record As Momentum Continues -- Market Talk

1 dec 2025, 18:46 UTC

Marktinformatie

Luxury Seen With Accelerating Growth Next Year -- Market Talk

1 dec 2025, 16:41 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

1 dec 2025, 16:41 UTC

Marktinformatie

Rapid Wage Growth in Canada to Keep BOC Sidelined -- Market Talk

1 dec 2025, 16:20 UTC

Marktinformatie

Yen Could Strengthen Further Against Dollar on Rate-Hike Prospects -- Market Talk

1 dec 2025, 16:00 UTC

Winsten

Strategy Helped Solve Its Bitcoin-Preferred Problem. Here's How. -- Barrons.com

1 dec 2025, 15:51 UTC

Acquisities, Fusies, Overnames

Goldman Makes a $2 Billion Bet on 'Boomer Candy' -- WSJ

1 dec 2025, 15:47 UTC

Marktinformatie

Global Equities Roundup: Market Talk

1 dec 2025, 15:47 UTC

Marktinformatie

Airbus Guidance Is at Risk -- Market Talk

1 dec 2025, 15:46 UTC

Acquisities, Fusies, Overnames

Synopsys Gets a New Investor. What to Know About Nvidia's Stake. -- Barrons.com

1 dec 2025, 15:33 UTC

Marktinformatie

Airbus Selloff May Be Overdone -- Market Talk

1 dec 2025, 15:26 UTC

Marktinformatie

Warming Forecast Pressures Natural Gas -- Market Talk

1 dec 2025, 15:23 UTC

Marktinformatie

Geopolitical Turmoil Supports Crude Oil -- Market Talk

1 dec 2025, 14:59 UTC

Acquisities, Fusies, Overnames

Goldman's Latest Acquisition Is a $2 Billion Bet on Active ETFs -- Barrons.com

Peer Vergelijking

Prijswijziging

Arrowhead Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

-7.02% neerwaarts potentieel

12 Maanden Prognose

Gemiddelde 49 USD -7.02%

Hoogste 80 USD

Laagste 17 USD

Gebaseerd op 10 Wall Street-analisten die 12-maands prijsdoelen bieden voor Arrowhead Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

10 ratings

Buy

Hold

Sell

Gebaseerd op 10 analisten die aandelenratings hebben gegeven aan Arrowhead Pharmaceuticals Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

11.5 / 12.23Steun & Weerstand

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

There is one bearish event.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Arrowhead Pharmaceuticals Inc

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.